Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that can result in severe muscle weakness and paralysis, loss of vision, respiratory failure and neuropathic pain.


There were 5 New Hires and Promotions in the #BioHealthCapitalRegion in the month of August! Check out all the #PeopleOnTheMove Here Facility Logix LLC Ceres Nanosciences, Inc. Vaccitech CRB


Healthcare giant Johnson & Johnson today announced the six winners of the Champions of Science Africa Innovation Challenge 2.0 at the 28th World Economic Forum on Africa in Cape Town.

The winning teams will get share of $300 000 prize pool, along with extensive mentoring and network building to support the expansion and sustainability of the companies and their programmes.


M. Javad Aman, PhD, President and CEO of Integrated BioTherapeutics, explains how his Montgomery County company is focused on discovery research for the development of new vaccines and therapies to fight emerging infectious diseases.


College Park, Maryland, will serve as a SBIR Road Tour stop for the state of Maryland, and will provide attendees with an opportunity to hear directly from the participating federal agency program managers that administer over 5,000 new awards annually. Register today for a one-on-one appointment with your choice of agencies!

The SBIR Road Tour is a national outreach effort connecting entrepreneurs working on advanced technologies to the country’s largest source of early stage funding – the SBIR/STTR programs. Also known as America’s Seed Fund, the SBIR/STTR programs provide over $3 billion in funding to small businesses each year in a wide variety of technology areas.


Organizers of the $150K "Make Your Medical Device Pitch for Kids!" competition today announced the 12 finalists who are advancing to the live pitch component of the competition scheduled for Sept. 22 during the 7th Annual Pediatric Device Innovation Symposium hosted by Children's National Health System. The pitch competition, sponsored by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), focuses on Neonatal Intensive Care Unit (NICU) innovations, a pediatric subspecialty that the Food and Drug Administration (FDA) identifies as having a significant unmet need for medical devices.

mockvsolutions logo

Making a therapeutic that contains biological components is just the start of creating a medicine. Then, biopharmaceutical companies must capture that drug and ensure that it’s free of contamination. New techniques and technologies can accomplish that capture and cleanup more simply and economically.


REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today announced an option and license agreement for exclusive worldwide rights to Clearside's proprietary, in-office SCS Microinjector™ for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other conditions for which anti-vascular endothelial growth factor (anti-VEGF) treatment is currently the standard of care. REGENXBIO plans to evaluate RGX-314 using Clearside's SCS Microinjector for in-office, non-surgical delivery into the suprachoroidal space, while continuing to advance its RGX-314 subretinal delivery program currently in development for wet AMD and DR.